On December 5, 2022 iBio, Inc. (NYSEA:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, reported that it will present two posters at the Antibody Engineering & Therapeutics Conference 2022 [AE&T] in San Diego, California, December 4-8 (Press release, iBioPharma, DEC 5, 2022, View Source [SID1234624786]). The AE&T Conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
iBio will highlight applications of iBio’s artificial intelligence-powered RubrYc Discovery Engine in the following posters:
"Epitope-Targeted Antibody Discovery with AI-Designed Structural Immunogens," including applications for two challenging targets, a PD-1 Agonist and the EGFRvIII tumor-specific epitope, presented by Alexander Taguchi, Ph.D., Director of Machine Learning.
"Fully Human & Developable Antibody Optimization Libraries Using Human Sequence-Trained AI and Mammalian Display," demonstrating the identification of a more potent PD-1 Agonist antibody, a CCR8 ADCC Cell Killing Assay, and use of the EGFRvIII tumor-specific epitope to target and kill tumor cells while preserving healthy cells, presented by Matthew Greving, Ph.D., Vice President of Platform Technology and Machine Learning.
The RubrYc Discovery Engine is designed to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. By combining proprietary epitope steering with an advanced library, the RubrYc Discovery Engine consistently delivers hits on difficult targets in a fraction of the time of traditional lead optimization.